Research and Markets: Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market" report to their offering.

Researchers Bust a Gut to Improve Gastrointestinal Disorders Market:

Drugs to treat gastrointestinal disorders are due to see a significant price drop, as patents run out and research takes off, according to a new report by healthcare experts GBI Research.

The new report* states that patients with disorders such as Irritable Bowel Syndrome (IBS), Crohn's disease, Ulcerative Colitis (UC), Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD) will experience a rush in new generic versions of popular medication, and new novel drugs with the hope of better results.

The market for gastrointestinal disorder therapeutics is being driven by increased stress, unhealthy eating habits, the growth of the global elderly population and an increased level of awareness among the general population, which has spurred on the rise of incidence and diagnosis over the recent past. Anxiety, unhealthy foods and advanced age can all be associated with changes in gastrointestinal physiology. However, gastrointestinal diseases still have a low diagnosis rate, and a fear of serious side effects may restrain market growth.

The gastrointestinal disorders therapeutics market is set to experience strong generic competition during the forecast period, as several major branded drugs used in to treat gastrointestinal disorders are set to expire during 2011-2015, including Nexium (esomeprazole magnesium), Aciphex (rabeprazole sodium), Tysabri (natalizumab) and Humira (adalimumab). This will result in a decline in the Annual Cost of Treatment (ACT), from $291 in 2011 to $261 in 2018 at a negative Compound Annual Growth Rate (CAGR) of 1.5%, although the launch of novel biologics will stabilize this drop.

However the market is set to witness a steady growth from 2015 onwards due to the anticipated entry of innovative new drugs, as the industry shows strong R&D activity in IBS, constipation, Crohn's disease and UC with effective and novel drug molecules. There are approximately 269 ongoing clinical trials in the gastrointestinal disorders therapeutics market, with the main focus being on Crohn's disease and UC. 42% of all ongoing clinical trials are in Phase II and 22% are in the late stages (Phase III and NDA-filed). This robust pipeline increases the chance of getting new drugs to market and may represent better treatment options with fewer side effects.

The Irritable Bowel Syndrome (IBS) and constipation therapeutics markets were valued at $722m and $1.7 billion in 2011, and are expected to grow at CAGRs of 13.7% and 11.1% to $1.8 billion and $3.6 billion respectively in 2018. This high growth rate is attributed to the strong pipeline dominated by First-In-Class (FIC) molecules such as recently launched Linzess (linaclotide). Others include Plecanatide, Xifaxan (rifaximin), Asimadoline and Naloxegol (PEG-naloxol), most of which have demonstrated high safety and efficacy profiles in clinical trials. There is a significant level of unmet need associated with current treatment options for IBS and constipation, and if these new therapies can address them, they will be able to command a price premium, thus driving the market.

Companies Mentioned:

- AstraZeneca

- Takeda Pharmaceutical Company

- Johnson & Johnson

- Eisai Co., Ltd.

- Abbott Laboratories

- Shire

- Salix Pharmaceuticals

For more information visit

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Source: Research and Markets